Core Insights - Novartis AG reported better-than-expected Q2 2025 results, with core earnings of $2.42 per share, surpassing the Zacks Consensus Estimate of $2.38 and up from $1.97 a year ago, driven by strong sales growth [1][6] - Revenues reached $14.05 billion, a 12% increase from the previous year, exceeding the Zacks Consensus Estimate of $14.04 billion [1][6] Sales Performance - On a constant currency basis, sales increased by 11%, supported by strong performances from key drugs including Kisqali, Entresto, Kesimpta, Scemblix, Leqvio, and Pluvicto [2][6] - Entresto's sales rose 22% to $2.36 billion, driven by heart failure indications in the U.S. and Europe, and hypertension indications in China and Japan, beating estimates [5][6] - Kisqali's sales surged 64% to $1.2 billion, with strong growth in the U.S. due to recent launches [8] - Kesimpta sales totaled $1.1 billion, up 33%, driven by increased demand [9] - Cosentyx sales increased 6% to $1.6 billion but missed estimates, impacting investor sentiment [7][6] - Pluvicto sales reached $454 million, up 30%, following FDA approval for earlier use, significantly expanding the eligible patient population [12] - Leqvio sales soared 61% to $298 million, driven by steady demand growth [13] Financial Guidance and Strategic Moves - Novartis raised its 2025 core operating income growth outlook to low teens, reflecting strong product and pipeline performance [6][16] - The company initiated a $10 billion share buyback plan, expected to be completed by 2027 [17] - Novartis acquired Regulus Therapeutics Inc. for $0.8 billion, with potential additional payments based on regulatory milestones [21] Management Changes - CFO Harry Kirsch announced his retirement, with Mukul Mehta appointed as the new CFO, effective March 15, 2026 [18]

Core Insights - Johnson & Johnson reported Q2 2025 earnings that exceeded analysts' expectations for both adjusted earnings and revenue, with revenue at $23.7 billion and adjusted EPS at $2.77 [1][2][6] - The company experienced strong sales momentum and progress in innovation, but underlying profit growth faced challenges due to patent expiries and higher costs [2][5] Financial Performance - Adjusted EPS for Q2 2025 was $2.77, slightly down 1.8% from $2.82 in Q2 2024, while revenue increased by 5.8% year-over-year [3][6] - GAAP EPS rose 18.7% to $2.29, and net earnings reached $5.54 billion, up 18.2% from the previous year [3][6] - Free cash flow decreased to $6.2 billion, down 17.4% from $7.51 billion a year ago [3][12] Business Segments - U.S. sales increased by 7.8% year-over-year, while international revenue grew by 3.2%, indicating stronger domestic performance [7] - In the Innovative Medicine division, sales rose 4.9%, driven by oncology and immunology products, despite a decline in STELARA impacting overall revenue [8] - MedTech sales increased by 7.3% to $8.54 billion, with significant contributions from cardiovascular products and new product launches [9][10] Regulatory and Pipeline Developments - The company achieved several regulatory milestones, including FDA approval for IMAAVY and positive EU opinions for oncology assets [11] - New clinical data supported the expansion of both immunology and oncology franchises, indicating a robust pipeline [11] Future Outlook - Management raised its full-year 2025 sales guidance to a midpoint of $93.4 billion, reflecting a 5.4% increase from the prior year [14] - Adjusted operational EPS target was also increased to a midpoint of $10.68, representing 7% year-on-year growth [14] - The company faces ongoing challenges from tariffs and competitive dynamics, particularly in orthopedics, which require close monitoring [15]

AI and Energy Infrastructure - The American big tech companies are allocating $320 billion (USD) in capital expenditure (capex) for the next year, surpassing the combined capex of the automotive and manufacturing industries [1][4] - A kilowatt of power is more valuable today than ever before due to the energy demands of AI [1] - Capital is flowing towards regions with stranded gas, such as Pennsylvania (Bacan, Perian, Marcelus), to convert gas to electricity for data centers [2] - Converting gas to electricity and then to intelligence is the core process of an AI factory [3] - Fiber optic cable permitting faces less resistance compared to pipelines and transmission lines [3] - Collocation is becoming a strategic move for companies seeking electricity and permits [4] Regulatory and Permitting Environment - The previous administration aimed to accelerate permitting for energy projects, including coal mines, uranium mines, and gas pipelines [5] - The environmental assessment (EA) and environmental impact statement (EIS) processes were previously used to obstruct infrastructure development [5] - The Department of Interior set a goal to complete environmental assessments in 14 days and EIS in 28 days, significantly faster than the typical multi-year timeframe [6]

Weed Rx: “Pharmaceutical cannabis is the biggest future for cannabis,” says Joel Stanley (left, with his brother Jared), founder of Ajna BioSciences, which has a botanical drug in the FDA pipeline. https://t.co/1yx4zLwQBD https://t.co/1yx4zLwQBD ...

Life Time Group Holdings (NYSE: LTH ) has seen quite positive performance over the past year, with the Street being slightly bullish on the expansion pipeline. Nonetheless, price targets seem to continue striking low numbers due to competition andEquity research analyst based in San Francisco. Mainly focused on tech and consumer companies that I have variant points of view on. Always looking to explore interesting business models through a practical, no-nonsense approach.Analyst’s Disclosure:I/we have a ben ...

Investment Rating - The report assigns a "Buy" rating for Bilibili Inc. (BILI) with a 12-month price target of $23.60, indicating a potential upside of 10.0% from the current price of $21.46 [1][17]. Core Insights - The management of Bilibili expressed confidence in delivering above-industry advertising growth in the coming years, supported by advancements in advertising technology and enhanced industry solutions [9][18]. - The gaming segment is expected to improve visibility with a new pipeline of games, including titles aimed at younger audiences and a long-term operational strategy for each game [9][22]. - The overall financial outlook shows significant revenue growth projections, with total revenue expected to increase from RMB 26,831.5 million in 2024 to RMB 36,608.4 million by 2027 [4][15]. Advertising Trends - Management highlighted a strong advertising growth trend, with key industries showing robust performance in 1H25, including a notable 82% year-over-year increase in related ad revenue [9][18]. - Specific advertising formats, such as splash screen ads and search performance ads, saw increases of 16% and 76% year-over-year, respectively, in 1H25 [18]. - The content-consumption industry experienced a 90% year-over-year increase in ad revenue, driven by significant growth in internet services and education sectors [18][19]. Gaming Strategy - Bilibili's gaming strategy focuses on developing games that resonate with young people's values and ensuring a long lifecycle of over five years for each title [9][22]. - Upcoming game releases include "Trickcal RE:VIVE" and "Escape from Duckov," with global launches planned for 2H25 [22][23]. - The company is shifting its monetization strategy towards cosmetic items, which has shown promising results in user engagement and revenue generation [23]. Financial Projections - Revenue is projected to grow at a compound annual growth rate (CAGR) of 19.1% from 2024 to 2025, with EBITDA expected to increase significantly from RMB 2,356.4 million in 2024 to RMB 4,531.7 million in 2025 [4][12]. - The earnings per share (EPS) is forecasted to turn positive by 2025, reaching RMB 5.63, with further growth anticipated in subsequent years [4][15]. - The report indicates a strong free cash flow yield, expected to rise from 2.3% in 2024 to 8.3% by 2027 [4][11]. Market Position - Bilibili's market capitalization is currently at $9.0 billion, with an enterprise value of $6.7 billion, positioning it favorably within the China Games, Entertainment, and Healthcare Tech sectors [4][11]. - The company has a strong advertising wallet share gain in the gaming sector, indicating a competitive edge against major players like Tencent and NetEase [18][19].

Weed Rx: “Pharmaceutical cannabis is the biggest future for cannabis,” says Joel Stanley (left, with his brother Jared), founder of Ajna BioSciences, which has a botanical drug in the FDA pipeline. https://t.co/Zc0kC8TGIb https://t.co/Zc0kC8TGIb ...

This hands-on workshop introduces Mastra.ai, a TypeScript framework that streamlines the development of agentic AI systems compared to traditional approaches using LangChain and vector databases. Participants will learn to build structured AI workflows with composable tools and reliable control, enabling them to create internal AI assistants that can handle requests like data cleaning, email drafting, and document summarization with minimal code. The session covers Mastra installation, running a local MCP s ...

Investment Ratings - Kuaishou: Buy rated, share price increased by 55% YTD and 28% post 1Q result [3] - Tencent Music: Buy rated, share price increased by 80% YTD and 37% post 1Q result [5] - NetEase: Buy rated, share price increased by 52% YTD and 25% post 1Q result [11] - Focus Media: Buy rated, share price increased by 11% YTD and 8% post 1Q result [14] - Bilibili: Buy rated, share price increased by 31% YTD and 22% post 1Q result [18] Core Insights - The report highlights a strong rally in major games and entertainment names post 1Q25 results, driven by resilient growth profiles, disciplined competition, AI applications potential, and rising expectations on game pipelines [1] - Key focus areas for the upcoming earnings season include advertising outlook, game momentum into the summer peak season, AI applications monetization, and pricing strategies [2] - The report anticipates that further upside in share prices will require continued earnings delivery or new growth engines contributing to revenue growth in future years [1] Kuaishou - Kuaishou is expected to deliver in-line results for 2Q25 with a 12% year-over-year growth in ads and a 13% growth in GMV, with a 3Q25 outlook of 14% ads growth [3][4] - The company is positioned to improve sequential ads from 2Q onwards due to higher monetization efforts, despite competition from peers [4] - The revenue target for Kling AI has been raised from US$100 million to over US$140 million for FY25 [4] Tencent Music - Tencent Music is projected to achieve a 17% year-over-year growth in music revenue for 2Q25, with an ARPU increase of 9% [8] - The company is expected to maintain good momentum in ARPU due to lower discounts on SVIP subscriptions and new content initiatives [9] - Long-term growth visibility remains strong, with expectations of mid-teen year-over-year music revenue growth [10] NetEase - NetEase is expected to report a 15% year-over-year growth in game revenue for 2Q25, with operating profit increasing by 20% [11][12] - The company is focusing on updates for its 2026 game pipeline, with expectations of stable performance from legacy titles [13] - The stock is trading at 16X 2025E PE, with potential for further EPS upgrades [13] Focus Media - Focus Media's revenue is expected to increase by 1% year-over-year in 2Q25, with operating profit up by 3% [14] - The company anticipates a 6% year-over-year sales increase in 2H25 due to rising ad demand from internet and selective consumer players [15] - The collaboration with Alipay aims to target 400K devices across tier 1/2 locations [17] Bilibili - Bilibili's game sales are projected to increase by 58% year-over-year in 2Q25, with ads up by 18% [18] - The company is expected to face a high comparison in 2H24 but has reset market expectations lower, with potential catalysts from new game approvals [19] - Despite valuation concerns, Bilibili is expected to deliver faster than industry growth in ads and livestreaming [20] Price Targets and Estimates - For NetEase, revenue estimates for 2025-27E have been slightly adjusted downwards, while net profit estimates have been raised [21] - Focus Media's revenue estimates have been trimmed slightly, but the price target has been revised up to Rmb8.3 [21] - Across game coverage, price targets and estimates for XD have been raised due to solid new game releases and better profit margins [21]

Mr. . Bashir Ojulari thank you so much for taking the time to speak with Bloomberg Television. Of course, we're outside the OPEC seminar.It's been going on for a couple of days. I want to start off by asking you about the Opec+ Group eight decision to bring back extra barrels to the market over the weekend, a faster pace of putting back these barrels. Do you think that the timing was right to do this.Can the market handle it. Yes. Yes.I think, you know, the geopolitics of oil and gas, which you know very we ...